Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

- Histologically or cytologically confirmed locally advanced or metastatic stage IIIB or stage IV NSCLC receiving 21-day cycles of gemcitabine/carboplatin or gemcitabine/cisplatin - Life expectancy ≥ 12 weeks at the time of screening - Thrombocytopenia as evidenced by a platelet count ≤ 50 x 10^9/L during the qualifying cycle of chemotherapy, OR platelet count < 100 x 10^9/L on Day 22 of the qualifying cycle (for eligibility inclusion: ability to receive the same dose of chemotherapy on study), this criteria ensures that the patient must be dose delayed for platelet recovery - Ability to receive the same dose and schedule of chemotherapy during the first on-study treatment cycle as was given in the qualifying cycle (except Day 8 gemcitabine) - Absolute neutrophil count (ANC) ≥ 1,000/µL, hemoglobin ≥ 9.5 g/dL, and platelet count ≥ 100 x 10 ^9/L on Day 1 of the first on study chemotherapy treatment cycle - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at the time of screening - Adequate Liver function; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x upper limit of normal (ULN) (except for patients with a confirmed diagnosis of Gilbert's Syndrome) - Adequate renal function; serum creatinine < 1.5 x ULN

- Receipt of > 1 prior systemic chemotherapy regimen - Sepsis, disseminated coagulation or any other condition (i.e. immune [idiopathic] thrombocytopenic purpura [ITP], thrombotic thrombocytopenic purpura [TTP], hemolytic uremic syndrome [HUS]) that may exacerbate thrombocytopenia - History of unstable angina, congestive heart failure, uncontrolled hypertension (diastolic > 100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year of screening ) myocardial infarction - History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 1 year of screening - History of pulmonary embolism or other venous thrombosis within 1 year of screening (except for catheter-related clots) - Use of any nitrosourea or mitomycin-C within 6 weeks of screening - Have received any thrombopoietic growth factor or related substance - Have received granulocyte macrophage colony stimulating factor (GM-CSF) within the last 4 weeks prior to screening - Have received any experimental therapy within 4 weeks prior to screening - Have ever received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening) - Known hypersensitivity to any recombinant E. coli-derived product.